Tislelizumab Versus Docetaxel in Patients With Previously Treated Advanced NSCLC (RATIONALE-303): A Phase 3, Open-Label, Randomized Controlled Trial

多西紫杉醇 医学 内科学 肿瘤科 打开标签 随机对照试验 化疗
作者
Caicun Zhou,Dingzhi Huang,Yun Fan,Xinmin Yu,Yunpeng Liu,Yongqian Shu,Zhiyong Ma,Ziping Wang,Ying Cheng,Jie Wang,Sheng Hu,Zhihua Liu,Elena V Poddubskaya,Umut Dişel,Andrey L. Akopov,Mikhail Vladimirovich Dvorkin,Wenjuan Zheng,Yiyuan Ma,Yan Wang,Songzi Li
出处
期刊:Journal of Thoracic Oncology [Elsevier BV]
卷期号:18 (1): 93-105 被引量:133
标识
DOI:10.1016/j.jtho.2022.09.217
摘要

INTRODUCTION: The phase 3 RATIONALE-303 trial (NCT03358875) investigated the efficacy and safety of tislelizumab versus docetaxel in pretreated patients with advanced NSCLC. Here, we report the efficacy and safety results and describe the exploratory biomarker analyses. METHODS: every 3 weeks. Co-primary end points were overall survival (OS) in the intent-to-treat (ITT) and programmed death-ligand 1 (PD-L1) tumor cell expression greater than or equal to 25% populations. The exploratory biomarker analyses included PD-L1 expression, tumor mutation burden, and gene expression profile. RESULTS: At the prespecified interim analysis (August 10, 2020), the co-primary end point of OS in the ITT population was met, with a statistically significant and clinically meaningful improvement in OS with tislelizumab versus docetaxel (median 17.2 versus 11.9 mo, respectively; hazard ratio [HR] = 0.64, p < 0.0001). At the final analysis (July 15, 2021), the other co-primary end point of OS in the PD-L1 tumor cell greater than or equal to 25% population was further met (median 19.3 versus 11.5 mo, respectively; HR = 0.53, p < 0.0001), and OS continued to improve in the ITT population (median 16.9 versus 11.9 mo, respectively, HR = 0.66). Exploratory biomarker analyses revealed the potential association of NOTCH1-4 mutations with improved tislelizumab efficacy for both OS and progression-free survival, whereas tissue tumor mutation burden correlated with progression-free survival benefit, but not OS benefit. No new safety signals were identified. CONCLUSIONS: Tislelizumab was found to have a significantly improved and long-term clinical benefit in OS versus docetaxel in pretreated patients with advanced NSCLC, regardless of PD-L1 expression.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
pkfsp完成签到,获得积分10
1秒前
Wx5211314发布了新的文献求助10
2秒前
徐自谦发布了新的文献求助10
2秒前
2秒前
传奇3的应助被凶狠的乌龟采纳,获得10
2秒前
疏水无纺布完成签到,获得积分10
3秒前
852的应助被超级馒头采纳,获得10
3秒前
3秒前
白云黑土完成签到,获得积分10
3秒前
彭于晏的应助被Zhou采纳,获得30
3秒前
雪碧发布了新的文献求助10
3秒前
4秒前
4秒前
二岁发布了新的文献求助10
4秒前
hc发布了新的文献求助10
4秒前
一一发布了新的文献求助10
4秒前
4秒前
5秒前
pkfsp发布了新的文献求助10
5秒前
小黎完成签到,获得积分10
6秒前
6秒前
7秒前
拼搏映菡完成签到,获得积分10
7秒前
7秒前
香蕉觅云的应助被sgybws采纳,获得10
7秒前
实验室发布了新的文献求助200
7秒前
bkagyin的应助被取个名儿吧采纳,获得10
8秒前
111完成签到,获得积分10
8秒前
9秒前
9秒前
搞怪乐驹的应助被他说采纳,获得10
9秒前
Chdhhc完成签到,获得积分10
9秒前
9秒前
万能图书馆的应助被pkfsp采纳,获得10
9秒前
10秒前
盛夏完成签到 ,获得积分20
10秒前
政zheng发布了新的文献求助10
10秒前
木羽发布了新的文献求助10
10秒前
flora发布了新的文献求助10
11秒前
小勋完成签到,获得积分10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8182178
求助须知:如何正确求助?哪些是违规求助? 9571839
关于积分的说明 21820273
捐赠科研通 7778694
什么是DOI,文献DOI怎么找? 3433632
关于科研通互助平台的介绍 2557802
邀请新用户注册赠送积分活动 2479657